Are we ready for translational research based on material and data from the Danish CancerBiobank and can we gain new knowledge from biobank registration?
APMIS · 2023
DOI: 10.1111/apm.13348 ↗Kurz gefasst
Fachartikel in der Zeitschrift APMIS, 2023. Verfasst von Estrid V S Høgdall und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Unit, Department of Pathology, Bio- and GenomeBank Denmark, Herlev Hospital, Copenhagen University, Herlev, Denmark. Hauptthemen laut MEDLINE: Adenocarcinoma, Clear Cell, Ovarian Neoplasms. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bio‐and GenomeBank, Denmark (RBGB) is a nationwide infra‐structure. Danish CancerBiobank (DCB) is a biobank in RBGB. The aim is to describe the degree of biological material collected and stored in DCB for patients diagnosed with primary ovarian cancer registered in The Danish Gynecologic Cancer Database (DGCD). Furthermore, to investigate the concordance between predicted organ of disease registered in RBGB at time of sampling (presumed diagnosis) with final diagnosis for patient. Data extraction from DGCD and DCB. Biological materials are present for 1.347 (62%) of 2.172 patients with primary ovarian cancer (OC). The median age of OC patients were 68 years (range: 18–90 years). Median age of patients with biological material in DCB was 67 years and for patients without biological material in DCB 69 years (p ≤ 0.0001). The histological subtypes for the 1347 OC patients with biological material were 911 (68%) serous adenocarcinoma, 97 (7%) endometrioid adenocarcinoma, 80 (6%) mucinous adenocarcinoma, 58 (4%) clear cell carcinoma, and for 201 (15%) no information were registered. For 327 patients (24%), the presumed diagnosis was hematological with a final diagnosis of OC. Using clinical data and biological material including pre‐analytical data regarding the biological material the possibility for translational research is optimal. Furthermore, information registered through daily working procedures may propose the need for additional biomarkers to aid clinicians to stratify patients to treatment in correct fast‐track packages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Unit, Department of Pathology, Bio- and GenomeBank Denmark, Herlev Hospital, Copenhagen University, Herlev, Denmark.
- Department of Gynecology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.
ORCID-Profile: Estrid V S Høgdall
Zitieren
APA
Høgdall, E. V. S., Christensen, I. J., & Høgdall, C. (2023). Are we ready for translational research based on material and data from the Danish CancerBiobank and can we gain new knowledge from biobank registration?. APMIS. https://doi.org/10.1111/apm.13348
Vancouver
Høgdall EVS, Christensen IJ, Høgdall C. Are we ready for translational research based on material and data from the Danish CancerBiobank and can we gain new knowledge from biobank registration?. APMIS. 2023. doi:10.1111/apm.13348
BibTeX
@article{Hgdall2023,
author = {Høgdall, Estrid V S and Christensen, Ib Jarle and Høgdall, Claus},
title = {Are we ready for translational research based on material and data from the Danish CancerBiobank and can we gain new knowledge from biobank registration?},
journal = {APMIS},
year = {2023},
doi = {10.1111/apm.13348}
}
EUVIMED